Clear Street’s Drugs Made In America Acquisition Corp Units DMAAU Stock Holding History

Clear Street’s Portfolio DMAAU Stock Details DMAAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$106K	Buy	10,005 +5	+0.1%	+$54	﹤0.01%	817
2026 Q1	$105K	Sell	10,000 -81,219	-89%	-$855K	﹤0.01%	618
2025 Q4	$957K	Buy	91,219 +43,736	+92%	+$459K	﹤0.01%	298
2025 Q3	$494K	Buy	47,483 +1,563	+3%	+$16.4K	﹤0.01%	286
2025 Q2	$474K	Buy	45,920 +40,071	+685%	+$410K	﹤0.01%	165
2025 Q1	$59.5K	Buy	+5,849	New	+$59K	﹤0.01%	173

Other funds holding DMAAU

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Clear Street's DMAAU Position: Q2 2026 in Review

Clear Street increased its Drugs Made In America Acquisition Corp Units (DMAAU) stake by 0.05% in Q2 2026, buying an estimated $54 and bringing the position to 10,005 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #817.

Clear Street first reported a position in DMAAU in Q1 2025 and has held it in 6 quarters since. The position peaked at $957K in Q4 2025. 2 funds tracked by Wall St. Rank hold DMAAU as of Q2 2026.

Clear Street held 10,005 shares of Drugs Made In America Acquisition Corp Units worth $106K as of Q2 2026.
Clear Street bought 5 Drugs Made In America Acquisition Corp Units shares in Q2 2026, an estimated $54.
Drugs Made In America Acquisition Corp Units made up ﹤0.01% of Clear Street's portfolio in Q2 2026, its #817 holding.
Clear Street first reported a position in Drugs Made In America Acquisition Corp Units in Q1 2025 and has held it in 6 quarters since.
Clear Street's Drugs Made In America Acquisition Corp Units position peaked at $957K in Q4 2025.
2 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Units as of Q2 2026.

Based on Clear Street's 13F filing for Q2 2026, filed 12 Aug 2026.